Lingtaike Biotech develops lncRNA-mediated targeted chimeric technology (lncTAC®) and the UNAST® platform to address the instability and delivery challenges of nucleic acid drugs. This technology enables the development of effective treatments for refractory cardiovascular, cerebrovascular, neurodegenerative, and oncology diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Nucleic acid drugs face significant challenges related to instability and effective delivery to target cells, hindering their therapeutic potential. Traditional drug development struggles to address previously undruggable targets, limiting treatment options for complex diseases. This is particularly true for refractory cardiovascular, cerebrovascular, neurodegenerative, and oncology diseases.
Solution
Lingtaike Biotech is developing a novel technology platform based on lncRNA-mediated targeted chimeric technology (lncTAC®) and the UNAST® platform to overcome the instability and delivery limitations of nucleic acid drugs. The lncTAC® technology utilizes lncRNAs to guide therapeutic payloads to specific cells and tissues, enhancing drug efficacy and reducing off-target effects. The UNAST® platform further stabilizes nucleic acid drugs and improves their delivery, maximizing their therapeutic impact. This combined approach enables the development of innovative treatments for a range of diseases, including cardiovascular, cerebrovascular, neurodegenerative, and oncology indications, by targeting previously inaccessible targets.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and clinicians seeking innovative solutions for treating complex and previously untreatable diseases.
Features
- lncTAC® (lncRNA-mediated Targeted Chimeric) technology for targeted drug delivery.
- UNAST® platform to enhance the stability and delivery of nucleic acid drugs.
- Focus on developing treatments for refractory cardiovascular diseases, cerebrovascular diseases, neurodegenerative diseases, and oncology.
- Targeting traditionally "undruggable" targets to expand therapeutic possibilities.
- Development of innovative nucleic acid drugs with improved efficacy and safety profiles.